drugset
drugset / Trial / NCT01431391

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

NCT01431391 ↗

Phase 2 Completed 68 enrolled Dendreon
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response. This study also evaluated the safety of sipuleucel-T and ADT treatment, immune system responses over time, the characteristics of sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.

Timeline

Start
2011-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Leuprolide Other / unclassified 45 mg Other
Subject Sipuleucel-T Cell therapy — Other

Indications

prostate adenocarcinoma